問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Koo Foundation Sun Yat-Sen Cancer Center (在職)

Division of Others-

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

邱倫瑋
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

40Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱倫瑋

List

47Cases

2025-03-01 - 2029-03-01

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study

  • Condition/Disease

    Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low or Intermediate-1 Risk According to DIPSS Plus (HOPE-PMF): The Core Study and Its Extension Study

  • Test Drug

    injection

Participate Sites
14Sites

Recruiting14Sites

2023-06-12 - 2027-05-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

2008-06-01 - 2012-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-06-01 - 2024-02-27

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2023-08-01 - 2028-03-15

Phase I

Active
FONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.

  • Condition/Disease

    Ovarian Cancer、 Lung Adenocarcinoma

  • Test Drug

    AZD5335 AZD5305

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-06-01 - 2027-09-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors

  • Condition/Disease

    Chronic Lymphocytic Leukemia 、Small Lymphocytic Lymphoma

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

2023-08-01 - 2027-04-30

Phase I/II

Active
A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination with Radiotherapy and Temozolomide in Subjects with Solid Tumors or Newly Diagnosed Glioblastoma

  • Condition/Disease

    Newly Diagnosed Glioblastoma

  • Test Drug

    NBM-BMX

Participate Sites
4Sites

Recruiting4Sites

2019-03-06 - 2022-02-28

Phase II

Active
Phase 2 open trial to evaluate the safety and efficacy of Telisotuzumab Vedotin (ABBV-399) in subjects with previously treated c-Met+ non-small cell lung cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    Telisotuzumab Vedotin (ABBV-399)

Participate Sites
11Sites

Recruiting11Sites

2022-09-01 - 2025-12-31

Phase I

Active
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ABBV-400

Participate Sites
11Sites

Not yet recruiting3Sites

Recruiting8Sites

2024-08-01 - 2028-03-31

Phase II

Active
A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA)

  • Condition/Disease

    Lung Cancer

  • Test Drug

    錠劑

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB